Search results for " tumor"

showing 10 items of 3819 documents

Intervención psicoeducativa en el alumnado con cáncer. Trayectoria profesional e investigadora en esta materia de la profesora Claudia Grau Rubio

2014

Se describe la trayectoria profesional e investigadora de la profesora Claudia Grau Rubio desde el año 1983,con respecto a la temática "intervención psicoeducativa en el alumnado con cáncer".

oncología pediátrica cáncer infantil. tumores pediátricos SNC familia educación
researchProduct

Paragangliomi cervicali: diagnosi e trattamento

2006

open surgerycarotid body tumorSettore MED/22 - Chirurgia Vascolarecarotid arteries.
researchProduct

Potential use of organotin(IV)-tripetide complexes as stopper in tumor cells growth.

2008

organotin(IV) tripeptide tumor cellsSettore CHIM/03 - Chimica Generale E Inorganica
researchProduct

Activation of the p38MAPK cascade is associated with upregulation of TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS.

2005

Phosphorylated p38 mitogen-activated protein kinase (p38MAPK), but not activated c-jun-N-terminal kinase (JNK), increases in the motor neurons of transgenic mice overexpressing ALS-linked SOD1 mutants at different stages of the disease. This effect is associated with a selective increase of phosphorylated MKK3-6, MKK4 and ASK1 and a concomitant upregulation of the TNFalpha receptors (TNFR1 and TNFR2), but not IL1beta and Fas receptors. Activation of both p38 MAPK and JNK occurs in the activated microglial cells of SOD1 mutant mice at the advanced stage of the disease; however, this effect is not accompanied by the concomitant activation of the upstream kinases ASK1 and MKK3,4,6, while both …

p38 mitogen-activated protein kinasesMAP Kinase Kinase 3Mice TransgenicMAP Kinase Kinase 6BiologyMAP Kinase Kinase Kinase 5p38 Mitogen-Activated Protein KinasesReceptors Tumor Necrosis FactorCellular and Molecular NeuroscienceMiceSuperoxide Dismutase-1Downregulation and upregulationAnimalsHumansASK1RNA Messengerfas ReceptorPhosphorylationReceptorProtein kinase AMolecular BiologyP38MAPK cascadeMotor NeuronsKinaseSuperoxide DismutaseTumor Necrosis Factor-alphaAmyotrophic Lateral SclerosisJNK Mitogen-Activated Protein KinasesReceptors Interleukin-1Cell BiologyCell biologyEnzyme ActivationMice Inbred C57BLDisease Models AnimalTumor Necrosis Factor Decoy ReceptorsSpinal CordReceptors Tumor Necrosis Factor Type IDisease ProgressionTumor necrosis factor alphaSignal TransductionMolecular and cellular neurosciences
researchProduct

Genetic profile and immunohistochemical study of clear cell renal carcinoma: Pathological-anatomical correlation and prognosis.

2021

Abstract Introduction Renal cell carcinoma (RCC) accounts for 2–3% of all tumors being the most frequent solid lesion in the kidney. Objective To determine what genetic alterations and immunohistochemical (IHC) of clear cell renal carcinoma (ccRCC) are associated with prognosis and tumor aggressiveness. Patients and Methods Experimental analytical study with 57 patients who underwent radical and partial nephrectomy between 2005 and 2011, all with diagnosis of ccRCC and minimum post-operative follow-up of 36 months. The pathological study included IHC determination of biomarkers associated (CAIX, CAM 5.2, CD10, c-erbB-2, EGFR, HIF-1a, Ki67, MDM2, PAX-2 y 8, p53, survivin and VEGFR 1 and 2). …

p530301 basic medicineMaleCancer Researchmedicine.medical_treatmentGastroenterologyNephrectomy0302 clinical medicineFHITRenal cell carcinomaCDKN2ANeoplasm MetastasisClear cell renal carcinomaRC254-282KidneyBRCA1 y 2Neoplasms. Tumors. Oncology. Including cancer and carcinogensCDKN2A: cyclin-dependent kinase Inhibitor 2AMiddle AgedPrognosisImmunohistochemistryNephrectomyKidney NeoplasmsMLPATumor BurdenSurvival Ratemedicine.anatomical_structureOncology030220 oncology & carcinogenesisImmunohistochemistryFemalemedicine.medical_specialty03 medical and health sciencesInternal medicinemedicineHumansMultiplex ligation-dependent probe amplificationCarbonic Anhydrase IXSurvival rateCarcinoma Renal CellAgedNeoplasm Stagingbusiness.industryCAIXmedicine.disease030104 developmental biologyNeoplasm GradingNeoplasm Recurrence LocalbusinessTranscriptomeFollow-Up StudiesCancer treatment and research communications
researchProduct

Expression of p63, p53 and ki-67 in patients with cervical intraepithelial neoplasia

2017

Objective: Cervical intraepithelial neoplasia (CIN) is a dysplastic process in cervical squamous epithelium and carries a risk of progression to cervical cancer. The aim of this study was to compare expression of three biomarkers named p53, p63 and Ki-67 in patients with various grades of cervical intraepithelial neoplasia and in a control group. Material and Method: 58 patients were enrolled in the study. Each patient underwent a colposcopy-guided biopsy of the cervix. Immunostaining for markers (p53, p63 and Ki-67) was performed on tissue samples of normal cases (n=10), CIN I (n=20), CIN II (n=14), and CIN III (n=14). Results: Our study showed a significant increase of the expression of t…

p530301 basic medicineUterine Cervical Neoplasmsurologic and male genital diseasesGastroenterology0302 clinical medicineYoung adultCervical cancerp63medicine.diagnostic_testbiologyvirus diseasesMiddle AgedImmunohistochemistryfemale genital diseases and pregnancy complicationsKoilocytesurgical procedures operativemedicine.anatomical_structure030220 oncology & carcinogenesisKi-67Disease ProgressionKi-67ImmunohistochemistryFemalelcsh:RB1-214Adultmedicine.medical_specialtyAdolescentCervical intraepithelial neoplasiaPathology and Forensic MedicineYoung Adult03 medical and health sciencesInternal medicineBiopsyBiomarkers Tumorlcsh:PathologymedicineHumansneoplasmsCervixCervical intraepithelial neoplasiabusiness.industryMembrane ProteinsUterine Cervical Dysplasiamedicine.diseaseKi-67 Antigen030104 developmental biologybiology.proteinTumor Suppressor Protein p53businessTurkish Journal of Pathology
researchProduct

Influence of aryl hydrocarbon- (Ah) receptor and genotoxins on DNA repair gene expression and cell survival of mouse hepatoma cells

2009

The aryl hydrocarbon receptor (AhR) mediates toxicity of a variety of environmental pollutants such as polycyclic aromatic hydrocarbons (PAHs) and dioxins. However, the underlying mechanisms and genetic programmes regulated by AhR to cause adverse effects but also to counteract poisoning are still poorly understood. Here we analysed the effects of two AhR ligands, benzo[a]pyrene (B[a]P), a DNA damaging tumour initiator and promotor and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a pure tumour promoter, on cell survival and on nucleotide excision repair (NER) gene expression. NER deals with so called "bulky" DNA adducts including those generated by enzymatically activated B[a]P. Therefore, t…

p53Aryl hydrocarbon receptor nuclear translocatorDNA RepairTumor suppressor geneCell SurvivalDNA damageDNA repairBlotting WesternDNA-Directed DNA Polymerasecis-PlatinBiologyToxicologyMiceLiver Neoplasms ExperimentalCell Line TumorGene expressionAnimals2378-Tetrachlorodibenzo-p-dioxinGeneAryl hydrocarbon receptorGene Expression ProfilingAryl Hydrocarbon Receptor Nuclear TranslocatorGenes p53Aryl hydrocarbon receptorMolecular biologyNucleotide excision repairBenzo[a]pyreneGene Expression RegulationReceptors Aryl HydrocarbonBiochemistrybiology.proteinEnvironmental PollutantsMutagensNucleotide excision repairToxicology
researchProduct

Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations

2004

Analysis of the genetic status of Ki-ras and p53 in primary colorectal carcinomas and matched colorectal liver metastasis from 30 patients reveals an overall heterogeneity both within and between the two tumoral tissues. Both genes were found mutated with a similar frequency in both tissues; however, identical mutations in primary tumor and matched metastasis were found less frequently in the case of the Ki-ras than the p53 gene. Only in three cases the same p53 and Ki-ras mutations found in the primary tumor were found also in the metastasis. In several metastatic specimens the DNA bearing a mutation detected also in the primary tumor appears significantly less abundant than the wild-type …

p53Colorectal cancerDNA Mutational AnalysisStatistics as TopicBiophysicsKi-raBiologyOncogene Protein p21(ras)medicine.disease_causeBiochemistryMetastasisMetastasischemistry.chemical_compoundSequence Homology Nucleic AcidmedicineHumansMolecular BiologyGeneRegulation of gene expressionMutationGene Expression ProfilingCarcinomaLiver NeoplasmsCell BiologySequence Analysis DNAmedicine.diseasePrimary tumorGene expression profilingGene Expression Regulation NeoplasticColorectal carcinomaGenes raschemistryMutationCancer researchTumor Suppressor Protein p53Colorectal NeoplasmsDNA
researchProduct

Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma

2018

Hepatocellular carcinoma (HCC) is a highly malignant tumor that responds very poorly to existing therapies, most probably due to its extraordinary inter- and intra-tumor molecular heterogeneity. The modest therapeutic response to molecular targeted agents underlines the need for new therapeutic approaches for HCC. In our study, we took advantage of well-characterized human HCC cell lines, differing in transcriptomic subtypes, DNA mutation and amplification alterations, reflecting the heterogeneity of primary HCCs, to provide a preclinical evaluation of the specific heat shock protein 90 (HSP90) inhibitor AUY922 (luminespib). Indeed, HSP90 is highly expressed in different tumor types, but it…

p53MaleCancer ResearchCellTranscriptome0302 clinical medicineHCCbeta CateninAged 80 and overLuminespibAUY922Liver NeoplasmsHep G2 CellsSorafenibMiddle AgedUp-RegulationGene Expression Regulation Neoplasticmedicine.anatomical_structureOncologyCaspases030220 oncology & carcinogenesisHepatocellular carcinomaFemaleNUPR1medicine.drugAdultSorafenibCarcinoma Hepatocellularβ-CateninMice NudeAntineoplastic AgentsSmall Molecule Libraries03 medical and health sciencesDownregulation and upregulationIn vivoCell Line TumormedicineHSP90AnimalsHumansHSP90 Heat-Shock ProteinsAgedCell growthbusiness.industryMcl-1IsoxazolesResorcinolsHCCSmedicine.diseasedigestive system diseasesMutationCancer researchTranscriptomebusinessInternational Journal of Cancer
researchProduct

Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achille’s heel to be exploited for the therapy of MYCN amplified neurob…

2012

The p53 oncosuppressor is very seldom mutated in neuroblastoma, but several mecha- nisms cooperate to its functional inactivation in this tumor. Increased MDM2 levels, due to genetic amplification or constitutive inhibition of p14ARF, significantly contribute to this event highlighting p53 reactivation as an attractive perspective for neuroblastoma treat- ment. In addition to its role in tumorigenesis, MYCN sensitizes untransformed and cancer cells to apoptosis. This is associated to a fine modulation of the MDM2-p53 pathway Indeed MYCN induces p53 and MDM2 transcription, and, by evoking a DNA damage response (DDR), it stabilizes p53 and its proapoptotic kinase Homeodomain Interacting Prote…

p53Programmed cell deathCancer ResearchHMGA1HIPK2Biologymedicine.disease_causelcsh:RC254-28203 medical and health sciencesNeuroblastoma0302 clinical medicineMDM2NeuroblastomaMYCNmedicineProtein kinase Aneoplasms030304 developmental biology0303 health sciencesKinaseHMGA1amedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensHMGA13. Good healthOncology030220 oncology & carcinogenesisCancer cellPerspective ArticleMDM2-antagonistsbiology.proteinCancer researchMdm2CarcinogenesisMDM2-antagonistFrontiers in Oncology
researchProduct